Can Science Turn Back the Biological Clock? The serious research behind rejuvenation, longer lives and the inconvenient matter of not dying The clock has a reverse gear. Possibly. Ageing used to sound like the ultimate non-negotiable contract: cells deteriorate, organs wear out, and eventually the warranty expires. Modern biology has complicated that tidy arrangement. Researchers can alter ageing-related processes in animals and, in some circumstances, restore youthful features in cells and tissues. That is not immortality. It is nevertheless a rather rude interruption to the idea that ageing only moves in one direction. First, what counts as “younger”? A lower reading on an epigenetic clock is not the same as extra birthdays. These clocks infer aspects of biological ageing from molecular patterns, often DNA methylation. A treatment might move a clock backwards without restoring every ageing organ—or reducing the chance of death. Genuine life extension means showing that treated people survive longer than comparable untreated people. That is a much higher bar, particularly when the experiment might take decades and the volunteers are understandably impatient. The experiments worth taking seriously The strongest conceptual breakthrough is cellular reprogramming. Yamanaka factors can return mature cells to a stem-cell-like state, demonstrating that some age-associated cellular features are resettable. Partial reprogramming aims for a more practical trick: rejuvenate cells without erasing what they are supposed to do. In animals, researchers have reported improvements in selected tissues and functions, although controlling tumour risk, cell identity and delivery remains difficult. Other credible avenues include clearing certain senescent cells, modifying nutrient-sensing pathways such as mTOR, and changing age-associated signals in blood. Experiments in mice have improved particular measures of function, and some interventions extend animal lifespan. None is a licence to translate mouse years directly into human years. Mice are excellent research subjects; they are notoriously poor at providing 40-year follow-up data. And humans? The awkward part Small human studies have reported shifts in epigenetic-age estimates and other biomarkers. The 2019 TRIIM pilot, for example, combined drugs aimed at thymus regeneration and reported a younger epigenetic-age signal. Its sample was tiny and it lacked a randomised control group. Such studies justify better trials, not a press release announcing that middle age has been cancelled. No therapy has yet convincingly demonstrated large-scale, whole-body age reversal in humans accompanied by an extension of maximum human lifespan. Could several treatments add up to decades? Potentially—but biology does not operate like a supermarket loyalty card. Clearing senescent cells, improving immune function and partially reprogramming tissue might address different problems. They might also interfere with one another, create cancer risks or deliver overlapping benefits that cannot simply be added. A speculative target of 10–20 years of biological rejuvenation is scientifically imaginable; it is not a measured collective effect, a consensus forecast or an established treatment outcome. Claims of 25–40 years or more are further into conjecture. What still needs fixingAgeing includes accumulated DNA mutations, damaged proteins, mitochondrial dysfunction, extracellular cross-links, altered immune responses and dwindling regenerative capacity. Making a skin cell look younger does not automatically repair an artery, remove a tumour precursor or restore a brain. A credible whole-body therapy would need durable improvements across multiple systems, manageable adverse effects and eventually better survival—not merely a flattering molecular portrait. The verdict Science has demonstrated that parts of the ageing process are modifiable and, in experimental settings, reversible. It has not demonstrated that a person can safely subtract decades from their whole-body biological age, let alone bank those decades as extra life. The sensible position is neither “death is solved” nor “nothing can be done.” The research is real. The ceiling is unknown. The marketing department, as usual, has arrived before the clinical trial. Further reading Takahashi & Yamanaka (2006), Cell — induction of pluripotent stem cells. Ocampo et al. (2016), Cell — partial reprogramming and ageing hallmarks in mice. Lu et al. (2020), Nature — reprogramming factors and visual function in mice. Fahy et al. (2019), Aging Cell — TRIIM pilot and epigenetic-age findings. López-Otín et al. (2023), Cell — updated hallmarks of ageing.